These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 27120579)

  • 1. Evaluation of Refractive Errors and Ocular Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity.
    Gunay M; Sekeroglu MA; Bardak H; Celik G; Esenulku CM; Hekimoglu E; Bardak Y
    Strabismus; 2016 Jun; 24(2):84-8. PubMed ID: 27120579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP).
    Etezad Razavi M; Shoeibi N; Hassanzadeh S; Kianmehr S; Bakhtiari E
    Strabismus; 2020 Mar; 28(1):49-54. PubMed ID: 31790628
    [No Abstract]   [Full Text] [Related]  

  • 3. Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy.
    Kuo HK; Sun IT; Chung MY; Chen YH
    Ophthalmologica; 2015; 234(4):211-7. PubMed ID: 26393895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
    Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
    Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
    Gunay M; Sukgen EA; Celik G; Kocluk Y
    Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
    Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA;
    JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refractive and biometrical characteristics of children with retinopathy of prematurity who received laser photocoagulation or intravitreal ranibizumab injection.
    Lu X; Zeng X; Chen M; Fan Z; Zheng L; Tian Y; Zhang S; He JC; Zhang G
    Graefes Arch Clin Exp Ophthalmol; 2022 Oct; 260(10):3213-3219. PubMed ID: 35546637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurodevelopmental Outcomes after Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity: A Prospective Case-Control Study.
    Fan YY; Huang YS; Huang CY; Hsu JF; Shih CP; Hwang YS; Yao TC; Lai CC; Wu WC
    Ophthalmology; 2019 Nov; 126(11):1567-1577. PubMed ID: 30954553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity.
    Kıran Yenice E; Petriçli İS; Kara C
    Int Ophthalmol; 2023 Jul; 43(7):2197-2202. PubMed ID: 36522564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser.
    Isaac M; Mireskandari K; Tehrani N
    J AAPOS; 2015 Apr; 19(2):140-4. PubMed ID: 25892041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes.
    Chen YH; Chen SN; Lien RI; Shih CP; Chao AN; Chen KJ; Hwang YS; Wang NK; Chen YP; Lee KH; Chuang CC; Chen TL; Lai CC; Wu WC
    Eye (Lond); 2014 Sep; 28(9):1080-6; quiz 1087. PubMed ID: 25104736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurity.
    Pawar N; Somyashree D; Meenakshi R; Maheshwari D; Mohideen S; Sithiq Uduman M
    Indian J Ophthalmol; 2023 Jun; 71(6):2561-2568. PubMed ID: 37322680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
    Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
    Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity.
    Murakami T; Sugiura Y; Okamoto F; Okamoto Y; Kato A; Hoshi S; Nagafuji M; Miyazono Y; Oshika T
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2849-2855. PubMed ID: 33744981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.
    Tan QQ; Christiansen SP; Wang J
    PLoS One; 2019; 14(12):e0225643. PubMed ID: 31790445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation.
    Chen YC; Chen SN
    Br J Ophthalmol; 2020 May; 104(5):691-696. PubMed ID: 31420328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
    Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
    Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
    Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
    Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
    Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal Change of Refractive Error in Retinopathy of Prematurity Treated With Intravitreal Bevacizumab or Laser Photocoagulation.
    Wiecek E; Akula JD; Vanderveen DK; Mantagos IS; Wu C; Curran AL; De Bruyn H; Peterson B; Fulton AB
    Am J Ophthalmol; 2022 Aug; 240():252-259. PubMed ID: 35367438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.